Built a massive free database & reports at blossomanalysis.com | ✉️ subscribe to The Bloom for weekly updates | Tweet about psychedelic science & therapy
Find over 1400 psychedelic research papers in our updated database
📣 Filter by topic, from neuroscience to OCD
🥼 Only show the type of study you want to find (e.g. double-blind)
🌵 Get specific about which compound to show
blossomanalysis.com/papersloom.com/share/f96182f2b26d4…
In just over a week, I'll be joining Breaking Convention again. It's the most fun conference in the space, and I'm looking forward to seeing you all there. Get a 10% discount with code BLOSSOM10
I'm eager to hear your thoughts, reactions, and especially your ideas on how we can collaborate to overcome these barriers together.
Let's talk. And let's transform possibilities into realities.
psychedelicsandreimbursement…
This isn't just about research—it's personal. I believe passionately that psychedelic therapies can revolutionise mental healthcare. And as an industry, we have an obligation to ensure that innovation isn't just possible but accessible and affordable.
But it's not all barriers and challenges. Our report also illuminates clear pathways forward:
• Engage early and openly with payers and policymakers.
• Adopt innovative pricing models that align treatment costs with actual patient outcomes.
This question kept Martin Gisby and me up at night. After months of diving into Europe's complex healthcare systems, we've unpacked the challenges standing between patients and these transformative treatments.
We all know the incredible promise psychedelics hold for conditions like depression, PTSD, and addiction. But what happens after regulatory approval? How do these groundbreaking therapies actually reach the people who need them most?
I'm excited—and frankly, a little nervous—to share something we've been working on for the last 6 months: our new report on reimbursement pathways for psychedelic therapies in Europe supported by Norrsken Mind.
The full report is linked below 👇
This computational fMRI study (n=15) examines brain dynamics after DMT (iv; 20mg) administration, focusing on the onset of the psychedelic state. It reveals a peak destabilization of brain dynamics around 5 minutes post-administration and identifies a heightened reactivity phase, primarily affecting fronto-parietal and visual regions. The study links these changes to serotonin 5HT2a receptor density, suggesting these dynamics underpin the psychedelic state’s complexity and flexibility.
blossomanalysis.com/papers/d…
This randomized, double-blind, cross-over study (n=23) investigates LSD (100μg) effects after daily paroxetine (SSRI) or placebo administration in healthy participants. It finds paroxetine reduced negative LSD effects (“bad drug effect,” “anxiety,” “nausea”) while maintaining pleasant effects, and caused higher LSD concentrations (1.4-1.5x) due to CYP2D6 inhibition, suggesting no LSD dose adjustment is needed when combined with CYP2D6-inhibiting SSRIs.
buff.ly/0r3uTHd
This one-year observational follow-up study (n=66) examined the long-term outcomes of psilocybin (25 mg, 10 mg, 1 mg; COMP360) in treatment-resistant depression (TRD). Median time to depressive relapse was longest in the 25 mg group (92 days) compared to 10 mg (83 days) and 1 mg (62 days), with most participants relapsing by week 12. A post hoc analysis of those entering the follow-up study (n=58) found a more pronounced difference, with the 25 mg group maintaining benefits for 189 days. Adverse events were minimal, with one case of mild suicidal ideation in the 1 mg group.
buff.ly/XhFY3vp
This systematic review (s=8) analyses completed controlled trials of psychedelics for depression, including psilocybin, LSD, ayahuasca, and DMT, all in Phase II or I/II. It evaluates methodological patterns against the draft European Medicines Agency guideline revision, highlighting challenges such as unblinding, expectancy, and adverse event characterisation, while calling for larger studies to assess long-term efficacy and safety.
buff.ly/UkjckaF
This naturalistic longitudinal study (n=66) investigates the long-term effects of ayahuasca on mental health in adults with no prior exposure. Participants attending neo-shamanic ceremonies reported sustained improvements in depression, anxiety, stress, affect, personality traits, spirituality, and relationships up to 12 months. Individuals with depression or anxiety experienced lasting symptom reductions, while those without a diagnosis had short-term benefits. Alcohol and cannabis use decreased only at one month. Findings suggest ayahuasca’s mental health benefits persist, with varying trajectories of change over time.
buff.ly/TVueO8a